1.
Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for
Study
1.2.3. Key Market
Segmentations
2.
Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3.
Executive Summary
3.1. Overview of the
Market
3.2. Overview of Key
Market Segmentations
3.3. Overview of Key
Market Players
3.4. Overview of Key
Regions/Countries
3.5. Overview of Market
Drivers, Challenges, Trends
4.
Voice of Customer
5. Global Omics-Based
Clinical Trials Market Outlook
5.1.
Market Size & Forecast
5.1.1.
By Value
5.2.
Market Share & Forecast
5.2.1.
By Phase (Phase I, Phase II, Phase III, and Phase IV.)
5.2.2.
By Study Design (Expanded Access Studies, Interventional
Studies, and Observational Studies)
5.2.3.
By Indication (Cardiology, CNS Diseases, Genetic
Diseases, Immunology, Oncology, Respiratory Diseases, and Skin Diseases)
5.2.4.
By Region
5.2.5.
By Company (2022)
5.3.
Market Map
6. Asia Pacific Omics-Based
Clinical Trials Market Outlook
6.1.
Market Size & Forecast
6.1.1.
By Value
6.2.
Market Share & Forecast
6.2.1.
By Phase
6.2.2.
By Study Design
6.2.3.
By Indication
6.2.4.
By Country
6.3.
Asia Pacific: Country Analysis
6.3.1.
China Omics-Based Clinical Trials Market Outlook
6.3.1.1.
Market Size & Forecast
6.3.1.1.1.
By Value
6.3.1.2.
Market Share & Forecast
6.3.1.2.1.
By Phase
6.3.1.2.2.
By Study
Design
6.3.1.2.3.
By Indication
6.3.2.
India Omics-Based Clinical Trials Market Outlook
6.3.2.1.
Market Size & Forecast
6.3.2.1.1.
By Value
6.3.2.2.
Market Share & Forecast
6.3.2.2.1.
By Phase
6.3.2.2.2.
By Study
Design
6.3.2.2.3.
By
Indication
6.3.3.
Australia Omics-Based Clinical Trials Market Outlook
6.3.3.1.
Market Size & Forecast
6.3.3.1.1.
By Value
6.3.3.2.
Market Share & Forecast
6.3.3.2.1.
By Phase
6.3.3.2.2.
By Study
Design
6.3.3.2.3.
By
Indication
6.3.4.
Japan Omics-Based Clinical Trials Market Outlook
6.3.4.1.
Market Size & Forecast
6.3.4.1.1.
By Value
6.3.4.2.
Market Share & Forecast
6.3.4.2.1.
By Phase
6.3.4.2.2.
By Study
Design
6.3.4.2.3.
By
Indication
6.3.5.
South Korea Omics-Based Clinical Trials Market Outlook
6.3.5.1.
Market Size & Forecast
6.3.5.1.1.
By Value
6.3.5.2.
Market Share & Forecast
6.3.5.2.1.
By Phase
6.3.5.2.2.
By Study
Design
6.3.5.2.3.
By
Indication
7. Europe Omics-Based
Clinical Trials Market Outlook
7.1.
Market Size & Forecast
7.1.1.
By Value
7.2.
Market Share & Forecast
7.2.1.
By Phase
7.2.2.
By Study
Design
7.2.3.
By Indication
7.2.4.
By
Country
7.3.
Europe: Country Analysis
7.3.1.
France Omics-Based Clinical Trials Market Outlook
7.3.1.1.
Market Size & Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share & Forecast
7.3.1.2.1.
By Phase
7.3.1.2.2.
By Study
Design
7.3.1.2.3.
By
Indication
7.3.2.
Germany Omics-Based Clinical Trials Market Outlook
7.3.2.1.
Market Size & Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share & Forecast
7.3.2.2.1.
By Phase
7.3.2.2.2.
By Study
Design
7.3.2.2.3.
By
Indication
7.3.3.
Spain Omics-Based Clinical Trials Market Outlook
7.3.3.1.
Market Size & Forecast
7.3.3.1.1.
By Value
7.3.3.2.
Market Share & Forecast
7.3.3.2.1.
By Phase
7.3.3.2.2.
By Study
Design
7.3.3.2.3.
By
Indication
7.3.4.
Italy Omics-Based Clinical Trials Market Outlook
7.3.4.1.
Market Size & Forecast
7.3.4.1.1.
By Value
7.3.4.2.
Market Share & Forecast
7.3.4.2.1.
By Phase
7.3.4.2.2.
By Study
Design
7.3.4.2.3.
By
Indication
7.3.5.
United Kingdom Omics-Based Clinical Trials Market Outlook
7.3.5.1.
Market Size & Forecast
7.3.5.1.1.
By Value
7.3.5.2.
Market Share & Forecast
7.3.5.2.1.
By Phase
7.3.5.2.2.
By Study
Design
7.3.5.2.3.
By
Indication
8. North America Omics-Based
Clinical Trials Market Outlook
8.1.
Market Size & Forecast
8.1.1.
By Value
8.2.
Market Share & Forecast
8.2.1.
By Phase
8.2.2.
By Study
Design
8.2.3.
By
Indication
8.2.4.
By Country
8.3.
North America: Country Analysis
8.3.1.
United States Omics-Based Clinical Trials Market Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Phase
8.3.1.2.2.
By Study
Design
8.3.1.2.3.
By
Indication
8.3.2.
Mexico Omics-Based Clinical Trials Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Phase
8.3.2.2.2.
By Study
Design
8.3.2.2.3.
By
Indication
8.3.3.
Canada Omics-Based Clinical Trials Market Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Phase
8.3.3.2.2.
By Study
Design
8.3.3.2.3.
By
Indication
9. South America Omics-Based
Clinical Trials Market Outlook
9.1.
Market Size & Forecast
9.1.1.
By Value
9.2.
Market Share & Forecast
9.2.1.
By Phase
9.2.2.
By Study
Design
9.2.3.
By
Indication
9.2.4.
By Country
9.3.
South America: Country Analysis
9.3.1.
Brazil Omics-Based Clinical Trials Market Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Phase
9.3.1.2.2.
By Study
Design
9.3.1.2.3.
By
Indication
9.3.2.
Argentina Omics-Based Clinical Trials Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Phase
9.3.2.2.2.
By Study
Design
9.3.2.2.3.
By
Indication
9.3.3.
Colombia Omics-Based Clinical Trials Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Phase
9.3.3.2.2.
By Study
Design
9.3.3.2.3.
By
Indication
10. Middle East and Africa
Omics-Based Clinical Trials Market Outlook
10.1.
Market Size & Forecast
10.1.1. By Value
10.2.
Market Share & Forecast
10.2.1. By Phase
10.2.2. By Study Design
10.2.3. By Indication
10.2.4. By Country
10.3.
MEA: Country Analysis
10.3.1. South Africa Omics-Based
Clinical Trials Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1.
By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1.
By Phase
10.3.1.2.2.
By Study
Design
10.3.1.2.3.
By
Indication
10.3.2. Saudi Arabia Omics-Based
Clinical Trials Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1.
By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1.
By Phase
10.3.2.2.2.
By Study
Design
10.3.2.2.3.
By
Indication
10.3.3. UAE Omics-Based
Clinical Trials Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1.
By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1.
By Phase
10.3.3.2.2.
By Study
Design
10.3.3.2.3.
By
Indication
11.
Market Dynamics
11.1.
Drivers
11.2.
Challenges
12.
Market Trends & Developments
12.1.
Recent Developments
12.2.
Product Launches
12.3.
Mergers & Acquisitions
13.
Global Omics-Based Clinical Trials Market: SWOT Analysis
14. Porter’s Five Forces
Analysis
14.1.
Competition in the Industry
14.2.
Potential of New Entrants
14.3.
Power of Suppliers
14.4.
Power of Customers
14.5.
Threat of Substitute Product
15.
PESTLE Analysis
16.
Competitive Landscape
16.1. Parexel
International Corporation
16.1.1. Business Overview
16.1.2. Company Snapshot
16.1.3. Products &
Services
16.1.4. Financials (In case
of listed companies)
16.1.5. Recent Developments
16.1.6. SWOT Analysis
16.2. Pharmaceutical
Product Development (PPD)
16.2.1. Business Overview
16.2.2. Company Snapshot
16.2.3. Products &
Services
16.2.4. Financials (In case
of listed companies)
16.2.5. Recent Developments
16.2.6. SWOT Analysis
16.3. Charles River Laboratory
16.3.1. Business Overview
16.3.2. Company Snapshot
16.3.3. Products &
Services
16.3.4. Financials (In case
of listed companies)
16.3.5. Recent Developments
16.3.6. SWOT Analysis
16.4. ICON plc
16.4.1. Business Overview
16.4.2. Company Snapshot
16.4.3. Products &
Services
16.4.4. Financials (In case
of listed companies)
16.4.5. Recent Developments
16.4.6. SWOT Analysis
16.5. SGS SA
16.5.1. Business Overview
16.5.2. Company Snapshot
16.5.3. Products &
Services
16.5.4. Financials (In case
of listed companies)
16.5.5. Recent Developments
16.5.6. SWOT Analysis
16.6. Eli Lilly and Company
16.6.1. Business Overview
16.6.2. Company Snapshot
16.6.3. Products &
Services
16.6.4. Financials (In case
of listed companies)
16.6.5. Recent Developments
16.6.6. SWOT Analysis
16.7. Pfizer Inc.
16.7.1. Business Overview
16.7.2. Company Snapshot
16.7.3. Products &
Services
16.7.4. Financials (In case
of listed companies)
16.7.5. Recent Developments
16.7.6. SWOT Analysis
16.8. Covance Inc.
16.8.1. Business Overview
16.8.2. Company Snapshot
16.8.3. Products &
Services
16.8.4. Financials (In case
of listed companies)
16.8.5. Recent Developments
16.8.6. SWOT Analysis
16.9. Novo Nordisk
16.9.1. Business Overview
16.9.2. Company Snapshot
16.9.3. Products &
Services
16.9.4. Financials (In case
of listed companies)
16.9.5. Recent Developments
16.9.6. SWOT Analysis
16.10.Rebus Bio
16.10.1. Business Overview
16.10.2. Company Snapshot
16.10.3. Products &
Services
16.10.4. Financials (In case
of listed companies)
16.10.5. Recent Developments
16.10.6. SWOT Analysis
17. Strategic Recommendations
About Us & Disclaimer